A research led by Sergio P. Acebrón, Researcher Ikerbasque at the UPV/EHU, develops a key tool to visualize the immune response to abnormal DNA, opening new avenues for the treatment of diseases.

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Veeva Systems (NYSE: VEEV) today announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM study on Veeva ...

With symptoms that often mimic other respiratory conditions, ILD is frequently misdiagnosed or unrecognized. However, in the Philippines, hope is in the horizon.

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

The new initiative aims to improve early detection by increasing access to screening in communities where accessing care is ...

Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Tricuspid regurgitation (TR) is common in patients with atrial functional mitral regurgitation (AFMR) but its impact is not ...